Clinical Trial Update: A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5) [Phase 3]

View source ↗

Summary

Phase 3 ADEPT-5 is evaluating the safety and efficacy of KarXT plus KarX-EC for psychosis associated with Alzheimer's disease; the trial is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Psychosis

Drugs mentioned

• KarX-EC
• KarXT (xanomeline-trospium)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Alzheimer Disease, Psychosis | Phase 3 | Status: RECRUITING